Bausch + Lomb (NYSE:BLCO) Announces Earnings Results

Bausch + Lomb (NYSE:BLCO) posted its quarterly earnings data on Wednesday. The company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.35 by ($0.03), Zacks reports. Bausch + Lomb had a negative net margin of 6.13% and a positive return on equity of 2.42%. During the same quarter in the prior year, the business posted $0.25 EPS. The company’s revenue for the quarter was up 9.8% on a year-over-year basis.

Here are the key takeaways from Bausch + Lomb’s conference call:

• Reported record Q4 revenue of $1.405 billion and full‑year revenue of $5.101 billion, with Q4 Adjusted EBITDA of $330 million (up 27%) and a 23.5% EBITDA margin, highlighting strong operating leverage.
• 2026 guidance calls for full‑year revenue of $5.375–$5.475 billion (5%–7% constant‑currency growth) and Adjusted EBITDA of $1.0–$1.05 billion, implying continued margin expansion toward the company’s multi‑year targets.
• MIEBO drove blockbuster growth (FY revenue $316 million, Q4 $112 million, prescriptions >2 million) and management now sees peak sales potential exceeding $600 million, underpinning dry‑eye momentum.
• Pipeline and R&D milestones progressed: CE Mark submission for the Silera femtosecond laser expected soon and a first external study of a new bioactive contact‑lens material met expectations, keeping a 2028 launch timeline on track but still subject to further trials.
• Surgical business recovery post‑enVista recall: company says it returned to prior market levels ahead of plan, with premium IOLs up ~20% in Q4, supporting higher‑margin mix in implantables.

Bausch + Lomb Stock Down 2.1%

BLCO traded down $0.38 on Wednesday, reaching $17.35. 208,509 shares of the company traded hands, compared to its average volume of 363,954. The company has a market cap of $6.15 billion, a price-to-earnings ratio of -19.97, a PEG ratio of 0.99 and a beta of 0.61. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.51 and a quick ratio of 0.98. The stock’s 50 day moving average price is $17.02 and its 200-day moving average price is $15.80. Bausch + Lomb has a 52-week low of $10.45 and a 52-week high of $17.91.

Hedge Funds Weigh In On Bausch + Lomb

A number of hedge funds have recently modified their holdings of the stock. Balyasny Asset Management L.P. acquired a new stake in Bausch + Lomb during the fourth quarter valued at $1,589,000. Armistice Capital LLC acquired a new position in Bausch + Lomb in the 4th quarter worth about $324,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Bausch + Lomb during the 4th quarter worth about $397,000. PDT Partners LLC lifted its holdings in shares of Bausch + Lomb by 1.9% during the 4th quarter. PDT Partners LLC now owns 175,536 shares of the company’s stock valued at $2,998,000 after buying an additional 3,327 shares during the last quarter. Finally, Cetera Investment Advisers lifted its holdings in shares of Bausch + Lomb by 3.9% during the 4th quarter. Cetera Investment Advisers now owns 18,713 shares of the company’s stock valued at $320,000 after buying an additional 711 shares during the last quarter. 11.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Wall Street Zen upgraded Bausch + Lomb from a “hold” rating to a “buy” rating in a research report on Saturday, November 1st. Raymond James Financial reissued an “outperform” rating and issued a $19.00 price target (up previously from $18.00) on shares of Bausch + Lomb in a research note on Thursday, October 30th. Barclays raised their target price on shares of Bausch + Lomb from $16.00 to $17.00 and gave the stock an “equal weight” rating in a report on Friday, October 31st. Evercore set a $18.00 target price on shares of Bausch + Lomb and gave the stock an “in-line” rating in a research report on Monday, January 5th. Finally, Citigroup upgraded shares of Bausch + Lomb from a “neutral” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Thursday, December 11th. Four equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Bausch + Lomb has an average rating of “Hold” and an average price target of $17.42.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.